Zobrazeno 1 - 10
of 41
pro vyhledávání: '"James G. Kublin"'
Autor:
Zoe Moodie, One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes, Jack Heptinstall, Faatima Laher Omar, Kristen Cohen, Stephen C De Rosa, Lu Zhang, Nicole L Yates, Marcella Sarzotti-Kelsoe, Kelly E Seaton, Fatima Laher, Linda Gail Bekker, Mookho Malahleha, Craig Innes, Sheetal Kassim, Nivashnee Naicker, Vaneshree Govender, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Erica Lazarus, Maphoshane Nchabeleng, Amy M Ward, William Brumskine, Thozama Dubula, April K Randhawa, Nicole Grunenberg, John Hural, Jia Jin Kee, David Benkeser, Yutong Jin, Lindsay N Carpp, Mary Allen, Patricia D’Souza, James Tartaglia, Carlos A DiazGranados, Marguerite Koutsoukos, Peter B Gilbert, James G Kublin, Lawrence Corey, Erica Andersen-Nissen, Glenda E Gray, Georgia D Tomaras, M Juliana McElrath
Publikováno v:
J Infect Dis
Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisiti
Autor:
Koshlan Mayer-Blackwell, Andrew M. Johnson, Nicole Potchen, Simon S. Minot, Jack Heptinstall, Kelly Seaton, Sheetal Sawant, Xiaoying Shen, Georgia D. Tomaras, Andrew Fiore-Gartland, James G. Kublin
Publikováno v:
Frontiers in immunology. 13
Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesiz
Autor:
Maurine D Miner, Mark Hatherill, Vidya Mave, Glenda E Gray, Sharon Nachman, Sarah W Read, Richard G White, Anneke Hesseling, Frank Cobelens, Sheral Patel, Mike Frick, Theodore Bailey, Robert Seder, Joanne Flynn, Jyothi Rengarajan, Deepak Kaushal, Willem Hanekom, Alexander C Schmidt, Thomas J Scriba, Elisa Nemes, Erica Andersen-Nissen, Alan Landay, Susan E Dorman, Grace Aldrovandi, Lisa M Cranmer, Cheryl L Day, Alberto L Garcia-Basteiro, Andrew Fiore-Gartland, Robin Mogg, James G Kublin, Amita Gupta, Gavin Churchyard
Publikováno v:
The lancet. HIV. 9(11)
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-in
Autor:
Srilatha Edupuganti, Maria G. Pau, Magda Sobieszczyk, Merlin L. Robb, Johannes P. M. Langedijk, M. Juliana McElrath, Lorenz Scheppler, Michal Sarnecki, Susan Buchbinder, Dan H. Barouch, Ian Frank, Kristen W. Cohen, Joseph P. Nkolola, Stephen R. Walsh, Etienne Karita, Hong Van Tieu, Lawrence Corey, Julie A Ake, Guido Ferrari, Steven Nijs, Kenneth H. Mayer, Karen Buleza, Lindsey R. Baden, Katleen Callewaert, Nadine Rouphael, Galit Alter, Georgia D. Tomaras, Paul A. Goepfert, Dimitri Goedhart, Frank Wegmann, Colleen Kelly, James G. Kublin, Lauren Peter, Trevor A Crowell, David C. Montefiori, Frank Tomaka, Philipp Mann, Michael C. Keefer, Daniel J. Stieh, Zelda Euler, Hanneke Schuitemaker
Publikováno v:
The Lancet. HIV
Summary Background Bioinformatically designed mosaic antigens increase the breadth of HIV vaccine-elicited immunity. This study compared the safety, tolerability, and immunogenicity of a newly developed, tetravalent Ad26 vaccine with the previously t
Autor:
Philip Kotze, Fatima Laher, Mary Allen, Peter B. Gilbert, Jia J. Kee, Dishiki Jenny Kalonji, Carter Bentley, Susan W. Barnett, Tricia Philip, Craig Innes, Adrian Puren, Holly Janes, Millicent Atujuna, Nivashnee Naicker, M. Juliana McElrath, Philisiwe B. Makhoba, Gladys Kobane, Girisha Kistnasami, Katlego S. Mapetla, Zakir Gaffoor, Cleon N. Ncayiya, Sanjay Phogat, Vimla Naicker, Simbarashe Takuva, James G. Kublin, Linda-Gail Bekker, Nima S. Hejazi, David Benkeser, Niranjan Kanesa-thasan, Modulakgotla Sebe, Olivier Van Der Meeren, Yunda Huang, Bontle Modibedi, Pamela Mda, Mookho Malahleha, Mpho Sikhosana, Matsontso Mathebula, Pearl Selepe, Amy Ward, Lawrence Corey, Megan Jones, John Hural, Tania Adonis, Sheetal Kassim, Carlos Diaz Granados, Nicole Grunenberg, Shelly Ramirez, Doug Grove, Maphoshane Nchabeleng, Brittany Prigmore, Graeme Meintjes, Erica Lazarus, William Brumskine, Lubbe Wiesner, Nigel Garrett, Marguerite Koutsoukos, Thozama Dubula, Zoe Moodie, Glenda Gray, Nishanta Singh, Michele P. Andrasik
Publikováno v:
The New England journal of medicine. 384(12)
Background A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous
Autor:
John R. Mascola, John Hural, Lynn Morris, Erica Lazarus, Catherine Orrell, Hvtn, Juan C Hinojosa, Philip Andrew, Joseph Makhema, Myron S. Cohen, Fatima Laher, Allan C. deCamp, Carter Bentley, Estelle Piwowar-Manning, Lindsey R. Baden, Nyaradzo Mgodi, Julie E. Ledgerwood, Hptn Study Teams, Carolyn Williamson, Lawrence Corey, Nidhi Kochar, Nirupama Sista, Nicole Espy, James G. Kublin, M. Juliana McElrath, David C. Montefiori, Peter B. Gilbert, James I. Mullins, Shelly Karuna, Kyle E. Marshall, Deborah Donnell, Pamela G Mukwekwerere, Magdalena E. Sobieszczyk, David N. Burns, Robinson Cabello, Pedro Gonzales, Hptn, Jorge Sanchez, Glenda Gray, Erika Rudnicki, Srilatha Edupuganti, Yunda Huang, Ian Frank, Michal Juraska, Margarita M. Gomez Lorenzo, April K. Randhawa, Simbarashe Takuva, Javier R. Lama
Publikováno v:
The New England journal of medicine. 384(11)
Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the H
Autor:
Abby Isaacs, Janan Dietrich, Joan Dragavon, Maria P. Lemos, John Hural, Reena K Gulati, M J McElrath, Erica Lazarus, Michele P. Andrasik, Doug Grove, Eva Chung, Robert W. Coombs, Glenda Gray, Adrian Puren, Cecilia Morgan, Fatima Laher, James G. Kublin, Yunda Huang
Publikováno v:
J Acquir Immune Defic Syndr
Background Measurements of HIV exposure could help identify subpopulations at highest risk of acquisition and improve the design of HIV prevention efficacy trials and public health interventions. The HVTN 915 study evaluated the feasibility of self-a
Autor:
Maphoshane Nchabeleng, Fatima Laher, Glenda Gray, Linda-Gail Bekker, Gavin J. Churchyard, Koleka Mlisana, Rephaim Mpofu, Mary Allen, James G. Kublin, Kennedy Otwombe, M. Juliana McElrath
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0241708 (2021)
PLoS ONE
PLoS ONE
Benign ethnic neutropenia (BEN) is defined as a neutrophil count of 9 cells/L in healthy individuals and is more common in populations of certain ethnicities, e.g. African or Middle Eastern ethnicity. Neutrophil values are commonly included in eligib
Autor:
Lamar Ballweber Fleming, Craig Innes, Valentin Voillet, Lindsay N. Carpp, Anneta F Naidoo, M. Juliana McElrath, Peter B. Gilbert, Glenda Gray, Guido Ferrari, Nicole Grunenberg, Linda-Gail Bekker, Fatima Laher, Georgia D. Tomaras, Erica Andersen-Nissen, James G. Kublin, Ying Huang, Andrew Fiore-Gartland, Michael S. Harper
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predic
Autor:
Kathryn Therese. Mngadi, Vijay L. Mehra, Kristen W. Cohen, Glenda Gray, Shannon Grant, Zoe Moodie, Brodie Daniels, Marguerite Koutsoukos, Sanjay Phogat, Peter B. Gilbert, M. Juliana McElrath, Nonhlanhla N. Mkhize, Chenchen Yu, Georgia D. Tomaras, Olivier Van Der Meeren, Linda-Gail Bekker, James G. Kublin, Nicole Frahm, Carlos A. DiazGranados, Mary Allen, Lawrence Corey, Fatima Laher, Carter Bentley, Mookho Malahleha, Michael Pensiero, Lynn Morris, Kevin O. Saunders, Nicole L. Yates, Nicole Grunenberg, David C. Montefiori, Craig Innes
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
Background HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. Methods and findings A phase 1–2 randomized double-blind place